Acute Coronary Syndrome

Revisiting the Clinical Utility of High Sensitivity Cardiac Troponin I Assays

Revisiting the Clinical Utility of High Sensitivity Cardiac Troponin I Assays

By

The effects of using high-sensitivity cardiac troponin I assays in patients with suspected acute coronary syndrome were assessed.

New Clinical Chemistry Score More Sensitive, Specific Than hs-cTn in ACS

New Clinical Chemistry Score More Sensitive, Specific Than hs-cTn in ACS

A score based on the results of three laboratory tests has higher sensitivity and specificity than cardiac troponin alone for stratifying patients presenting with suspected acute coronary syndrome.

Ticagrelor Without Concomitant Aspirin No Better Than Standard DAPT in PCI

Ticagrelor Without Concomitant Aspirin No Better Than Standard DAPT in PCI

By

Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.

Radial Access Reduced Adverse Events in Intervention for Acute Coronary Syndrome

Radial Access Reduced Adverse Events in Intervention for Acute Coronary Syndrome

By

Net adverse cardiac events occurred in 15.2% of patients with radial access and 17.2% with femoral access while undergoing invasive therapies for acute coronary syndrome.

Low Rates of Increasing Statin Doses After MI in Diabetes

Low Rates of Increasing Statin Doses After MI in Diabetes

By

Up-titration to a high-intensity statin occurred in only 37.7% of patients with diabetes after an acute myocardial infarction.

Fewer adverse myocardial events in depressed patients treated with antidepressants after acute coronary syndrome

In this prospective cohort study, depressed patients with acute coronary syndrome who were treated with escitalopram were less likely to have major adverse cardiovascular events than those treated with placebo during a long follow-up period.

The Uncertain Association Between Abacavir and the Risk for Acute Myocardial Infarction

The Uncertain Association Between Abacavir and the Risk for Acute Myocardial Infarction

A higher prevalence of traditional cardiovascular risk factors may be partially responsible for the increased incidence of cardiovascular disease in people living with HIV.

Rapid MI Rule-Out Protocol Outperforms Older Assay

Rapid MI Rule-Out Protocol Outperforms Older Assay

By

The new rapid rule-out for MI protocol had sensitivity and negativity predictive values of 100% and a specificity of 86%.

Acute MI Rates Increased From 2014-2017 During Pregnancy, Puerperium

Acute MI Rates Increased From 2014-2017 During Pregnancy, Puerperium

Rate of acute myocardial infarction occurred at a rate of 1 per 12,400 for those hospitalized during pregnancy, puerperium.

Acute Coronary Syndrome Risk Elevated in Siblings of Patients With RA

Acute Coronary Syndrome Risk Elevated in Siblings of Patients With RA

By

Siblings of patients with rheumatoid arthritis appear to have an increased risk for acute coronary syndrome, which suggests there is a shared susceptibility between the 2 conditions.

Dabigatran May Reduce Major Vascular Complication Risk After Noncardiac Surgery

Dabigatran May Reduce Major Vascular Complication Risk After Noncardiac Surgery

By

Dabigatran may be associated with a risk reduction of major vascular complications in patients who develop a myocardial injury after noncardiac surgery.

Acute MI Diagnosis: 0/1 Hour Superior to 0/3 Hour Algorithm

Acute MI Diagnosis: 0/1 Hour Superior to 0/3 Hour Algorithm

By

The 0/1 hour algorithm was superior to the 0/3 hour algorithm for ruling out acute myocardial infarction.

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

Cardiovascular Outcomes in Patients With ACS, Diabetes Using Alirocumab

By

Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.

NSTEMI Risk for ICU Complications Predicted Using ACTION ICU Risk Score

NSTEMI Risk for ICU Complications Predicted Using ACTION ICU Risk Score

By

When patient risk was predicted using ACTION ICU model, the likelihood of a complication developing that required ICU care increased >10-fold from the lowest to the highest scores.

Aldosterone antagonist therapy linked to reduced mortality following STEMI without heart failure

In this meta-analysis of available randomized clinical trials, use of aldosterone antagonist therapy in patients with preserved ejection fraction following STEMI was associated with a reduction in overall mortality. In addition, aldosterone antagonist therapy was linked to a small increase in serum potassium and no overall difference in serum creatinine levels.

Amyloid-beta (1-40) is a strong predictor of mortality in acute coronary syndrome

Patients with the highest Aβ40 had the worst non-ST-segment elevation acute coronary syndrome risk profile and greater all-cause mortality.

Aldosterone Antagonists Improved Survival in STEMI Without Heart Failure

Aldosterone Antagonists Improved Survival in STEMI Without Heart Failure

By

Aldosterone antagonists significantly reduced the risk for mortality in patients with ST-segment elevation myocardial infarction without heart failure.

Adverse Change in Employment Post-MI Tied to Worse Outcomes

Adverse Change in Employment Post-MI Tied to Worse Outcomes

Patients with an adverse change in employment were more likely to report depression and have lower health status following a myocardial infarction.

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

By

Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.

CV Risks With Alogliptin in Type 2 Diabetes and Recent Acute Coronary Syndrome

CV Risks With Alogliptin in Type 2 Diabetes and Recent Acute Coronary Syndrome

Investigators conducted a randomized, double-blinded, placebo-trolled trial in patients with T2D after an acute coronary syndrome.

Elevated FGF-23 associated with recurrent cardiovascular events after acute coronary syndrome

Elevated FGF-23 concentration was associated with increased risk for adverse cardiovascular outcomes, including cardiovascular death and heart failure hospitalization, as well as an increased risk for all-cause mortality.

Liraglutide May Affect Clinical Outcomes of Myocardial Infarction in Type 2 Diabetes

Liraglutide May Affect Clinical Outcomes of Myocardial Infarction in Type 2 Diabetes

Liraglutide may reduce the incidence of myocardial infarction in patients who have a high cardiovascular risk with type 2 diabetes.

Oxygen Therapy in Acute MI Not Associated With Clinical Benefit

Oxygen Therapy in Acute MI Not Associated With Clinical Benefit

By

Patients with confirmed or suspected acute myocardial infarction do not benefit from supplemental oxygen therapy.

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ACS

FGF-23 concentrations in the top quartile were independently linked to greater risk for CV death and heart failure hospitalization.

Loading Atorvastatin Doses Before and After PCI in ACS for MACE Prevention

Loading Atorvastatin Doses Before and After PCI in ACS for MACE Prevention

By

Major adverse cardiovascular events were not reduced in patients with acute coronary syndrome undergoing planned percutaneous coronary intervention when given 2 loading doses of atorvastatin.

Cardiovascular Complications of COPD

Cardiovascular Complications of COPD

By

A 55-year-old man with chronic obstructive pulmonary disease reports having some mild chest pain.

Statin Prescription Trends in Women vs Men After Hospitalization for MI

Statin Prescription Trends in Women vs Men After Hospitalization for MI

By

Women are less likely than men to fill a high-intensity statin prescription following hospitalization for myocardial infarction.

Smoking Cessation Rates in Acute Coronary Syndrome With Varenicline

Smoking Cessation Rates in Acute Coronary Syndrome With Varenicline

By

Although varenicline was effective for short-term smoking cessation, more than half of the patients in the EVITA trial relapsed after 1 year.

Social Isolation, Loneliness May Increase AMI, Stroke Risk

Social Isolation, Loneliness May Increase AMI, Stroke Risk

Social isolation linked to increased mortality among individuals with history of AMI or stroke

Higher Myocardial Infarction Care Payments Improve Mortality

Higher Myocardial Infarction Care Payments Improve Mortality

Findings based on Medicare 30-day payments for both inpatient care and after discharge.

Sign Up for Free e-Newsletters